 | • レポートコード：MRC2-11QY12887 • 出版社/出版日：QYResearch / 2020年11月30日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、113ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬 |
| Single User | ￥585,000 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥877,500 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,170,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は尿管がん治療薬のグローバル市場について調査・分析したレポートです。種類別（デュルバルマブ、エリブリンメシル酸、ペンブロリズマブ、その他）市場規模、用途別（入院患者、外来患者）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別尿管がん治療薬の競争状況、市場シェア ・世界の尿管がん治療薬市場：種類別市場規模 2015年-2020年（デュルバルマブ、エリブリンメシル酸、ペンブロリズマブ、その他） ・世界の尿管がん治療薬市場：種類別市場規模予測 2021年-2026年（デュルバルマブ、エリブリンメシル酸、ペンブロリズマブ、その他） ・世界の尿管がん治療薬市場：用途別市場規模 2015年-2020年（入院患者、外来患者） ・世界の尿管がん治療薬市場：用途別市場規模予測 2021年-2026年（入院患者、外来患者） ・北米の尿管がん治療薬市場分析：米国、カナダ ・ヨーロッパの尿管がん治療薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの尿管がん治療薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の尿管がん治療薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの尿管がん治療薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Altor BioScience Corp、Eisai Co Ltd、Exelixis Inc、GlaxoSmithKline Plc、MedImmune LLC、Merck & Co Inc ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Market Analysis and Insights: Global Ureter Cancer Drugs Market
The global Ureter Cancer Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Ureter Cancer Drugs Scope and Market Size
Ureter Cancer Drugs market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Ureter Cancer Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Ureter Cancer Drugs market is segmented into
Durvalumab
Eribulin Mesylate
Pembrolizumab
Others
Segment by Application, the Ureter Cancer Drugs market is segmented into
In-Patient
Out-Patient
Regional and Country-level Analysis
The Ureter Cancer Drugs market is analysed and market size information is provided by regions (countries).
The key regions covered in the Ureter Cancer Drugs market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Ureter Cancer Drugs Market Share Analysis
Ureter Cancer Drugs market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Ureter Cancer Drugs business, the date to enter into the Ureter Cancer Drugs market, Ureter Cancer Drugs product introduction, recent developments, etc.
The major vendors covered:
Altor BioScience Corp
Eisai Co Ltd
Exelixis Inc
GlaxoSmithKline Plc
MedImmune LLC
Merck & Co Inc
…
1 Study Coverage
1.1 Ureter Cancer Drugs Product Introduction
1.2 Market Segments
1.3 Key Ureter Cancer Drugs Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Ureter Cancer Drugs Market Size Growth Rate by Type
1.4.2 Durvalumab
1.4.3 Eribulin Mesylate
1.4.4 Pembrolizumab
1.4.5 Others
1.5 Market by Application
1.5.1 Global Ureter Cancer Drugs Market Size Growth Rate by Application
1.5.2 In-Patient
1.5.3 Out-Patient
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Ureter Cancer Drugs Market Size, Estimates and Forecasts
2.1.1 Global Ureter Cancer Drugs Revenue 2015-2026
2.1.2 Global Ureter Cancer Drugs Sales 2015-2026
2.2 Global Ureter Cancer Drugs, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Ureter Cancer Drugs Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Ureter Cancer Drugs Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Ureter Cancer Drugs Competitor Landscape by Players
3.1 Ureter Cancer Drugs Sales by Manufacturers
3.1.1 Ureter Cancer Drugs Sales by Manufacturers (2015-2020)
3.1.2 Ureter Cancer Drugs Sales Market Share by Manufacturers (2015-2020)
3.2 Ureter Cancer Drugs Revenue by Manufacturers
3.2.1 Ureter Cancer Drugs Revenue by Manufacturers (2015-2020)
3.2.2 Ureter Cancer Drugs Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Ureter Cancer Drugs Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Ureter Cancer Drugs Revenue in 2019
3.2.5 Global Ureter Cancer Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Ureter Cancer Drugs Price by Manufacturers
3.4 Ureter Cancer Drugs Manufacturing Base Distribution, Product Types
3.4.1 Ureter Cancer Drugs Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Ureter Cancer Drugs Product Type
3.4.3 Date of International Manufacturers Enter into Ureter Cancer Drugs Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Ureter Cancer Drugs Market Size by Type (2015-2020)
4.1.1 Global Ureter Cancer Drugs Sales by Type (2015-2020)
4.1.2 Global Ureter Cancer Drugs Revenue by Type (2015-2020)
4.1.3 Ureter Cancer Drugs Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Ureter Cancer Drugs Market Size Forecast by Type (2021-2026)
4.2.1 Global Ureter Cancer Drugs Sales Forecast by Type (2021-2026)
4.2.2 Global Ureter Cancer Drugs Revenue Forecast by Type (2021-2026)
4.2.3 Ureter Cancer Drugs Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Ureter Cancer Drugs Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Ureter Cancer Drugs Market Size by Application (2015-2020)
5.1.1 Global Ureter Cancer Drugs Sales by Application (2015-2020)
5.1.2 Global Ureter Cancer Drugs Revenue by Application (2015-2020)
5.1.3 Ureter Cancer Drugs Price by Application (2015-2020)
5.2 Ureter Cancer Drugs Market Size Forecast by Application (2021-2026)
5.2.1 Global Ureter Cancer Drugs Sales Forecast by Application (2021-2026)
5.2.2 Global Ureter Cancer Drugs Revenue Forecast by Application (2021-2026)
5.2.3 Global Ureter Cancer Drugs Price Forecast by Application (2021-2026)
6 North America
6.1 North America Ureter Cancer Drugs by Country
6.1.1 North America Ureter Cancer Drugs Sales by Country
6.1.2 North America Ureter Cancer Drugs Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Ureter Cancer Drugs Market Facts & Figures by Type
6.3 North America Ureter Cancer Drugs Market Facts & Figures by Application
7 Europe
7.1 Europe Ureter Cancer Drugs by Country
7.1.1 Europe Ureter Cancer Drugs Sales by Country
7.1.2 Europe Ureter Cancer Drugs Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Ureter Cancer Drugs Market Facts & Figures by Type
7.3 Europe Ureter Cancer Drugs Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific Ureter Cancer Drugs by Region
8.1.1 Asia Pacific Ureter Cancer Drugs Sales by Region
8.1.2 Asia Pacific Ureter Cancer Drugs Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Ureter Cancer Drugs Market Facts & Figures by Type
8.3 Asia Pacific Ureter Cancer Drugs Market Facts & Figures by Application
9 Latin America
9.1 Latin America Ureter Cancer Drugs by Country
9.1.1 Latin America Ureter Cancer Drugs Sales by Country
9.1.2 Latin America Ureter Cancer Drugs Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Ureter Cancer Drugs Market Facts & Figures by Type
9.3 Central & South America Ureter Cancer Drugs Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa Ureter Cancer Drugs by Country
10.1.1 Middle East and Africa Ureter Cancer Drugs Sales by Country
10.1.2 Middle East and Africa Ureter Cancer Drugs Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Ureter Cancer Drugs Market Facts & Figures by Type
10.3 Middle East and Africa Ureter Cancer Drugs Market Facts & Figures by Application
11 Company Profiles
11.1 Altor BioScience Corp
11.1.1 Altor BioScience Corp Corporation Information
11.1.2 Altor BioScience Corp Description and Business Overview
11.1.3 Altor BioScience Corp Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Altor BioScience Corp Ureter Cancer Drugs Products Offered
11.1.5 Altor BioScience Corp Related Developments
11.2 Eisai Co Ltd
11.2.1 Eisai Co Ltd Corporation Information
11.2.2 Eisai Co Ltd Description and Business Overview
11.2.3 Eisai Co Ltd Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Eisai Co Ltd Ureter Cancer Drugs Products Offered
11.2.5 Eisai Co Ltd Related Developments
11.3 Exelixis Inc
11.3.1 Exelixis Inc Corporation Information
11.3.2 Exelixis Inc Description and Business Overview
11.3.3 Exelixis Inc Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Exelixis Inc Ureter Cancer Drugs Products Offered
11.3.5 Exelixis Inc Related Developments
11.4 GlaxoSmithKline Plc
11.4.1 GlaxoSmithKline Plc Corporation Information
11.4.2 GlaxoSmithKline Plc Description and Business Overview
11.4.3 GlaxoSmithKline Plc Sales, Revenue and Gross Margin (2015-2020)
11.4.4 GlaxoSmithKline Plc Ureter Cancer Drugs Products Offered
11.4.5 GlaxoSmithKline Plc Related Developments
11.5 MedImmune LLC
11.5.1 MedImmune LLC Corporation Information
11.5.2 MedImmune LLC Description and Business Overview
11.5.3 MedImmune LLC Sales, Revenue and Gross Margin (2015-2020)
11.5.4 MedImmune LLC Ureter Cancer Drugs Products Offered
11.5.5 MedImmune LLC Related Developments
11.6 Merck & Co Inc
11.6.1 Merck & Co Inc Corporation Information
11.6.2 Merck & Co Inc Description and Business Overview
11.6.3 Merck & Co Inc Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Merck & Co Inc Ureter Cancer Drugs Products Offered
11.6.5 Merck & Co Inc Related Developments
11.1 Altor BioScience Corp
11.1.1 Altor BioScience Corp Corporation Information
11.1.2 Altor BioScience Corp Description and Business Overview
11.1.3 Altor BioScience Corp Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Altor BioScience Corp Ureter Cancer Drugs Products Offered
11.1.5 Altor BioScience Corp Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Ureter Cancer Drugs Market Estimates and Projections by Region
12.1.1 Global Ureter Cancer Drugs Sales Forecast by Regions 2021-2026
12.1.2 Global Ureter Cancer Drugs Revenue Forecast by Regions 2021-2026
12.2 North America Ureter Cancer Drugs Market Size Forecast (2021-2026)
12.2.1 North America: Ureter Cancer Drugs Sales Forecast (2021-2026)
12.2.2 North America: Ureter Cancer Drugs Revenue Forecast (2021-2026)
12.2.3 North America: Ureter Cancer Drugs Market Size Forecast by Country (2021-2026)
12.3 Europe Ureter Cancer Drugs Market Size Forecast (2021-2026)
12.3.1 Europe: Ureter Cancer Drugs Sales Forecast (2021-2026)
12.3.2 Europe: Ureter Cancer Drugs Revenue Forecast (2021-2026)
12.3.3 Europe: Ureter Cancer Drugs Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Ureter Cancer Drugs Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Ureter Cancer Drugs Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Ureter Cancer Drugs Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Ureter Cancer Drugs Market Size Forecast by Region (2021-2026)
12.5 Latin America Ureter Cancer Drugs Market Size Forecast (2021-2026)
12.5.1 Latin America: Ureter Cancer Drugs Sales Forecast (2021-2026)
12.5.2 Latin America: Ureter Cancer Drugs Revenue Forecast (2021-2026)
12.5.3 Latin America: Ureter Cancer Drugs Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Ureter Cancer Drugs Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Ureter Cancer Drugs Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Ureter Cancer Drugs Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Ureter Cancer Drugs Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Ureter Cancer Drugs Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Ureter Cancer Drugs Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
Table 1. Ureter Cancer Drugs Market Segments
Table 2. Ranking of Global Top Ureter Cancer Drugs Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Ureter Cancer Drugs Market Size Growth Rate by Type 2020-2026 (K Pcs) & (US$ Million)
Table 4. Major Manufacturers of Durvalumab
Table 5. Major Manufacturers of Eribulin Mesylate
Table 6. Major Manufacturers of Pembrolizumab
Table 7. Major Manufacturers of Others
Table 8. Global Ureter Cancer Drugs Market Size Growth Rate by Application 2020-2026 (K Pcs)
Table 9. Global Ureter Cancer Drugs Market Size by Region (K Pcs) & (US$ Million): 2020 VS 2026
Table 10. Global Ureter Cancer Drugs Sales by Regions 2015-2020 (K Pcs)
Table 11. Global Ureter Cancer Drugs Sales Market Share by Regions (2015-2020)
Table 12. Global Ureter Cancer Drugs Revenue by Regions 2015-2020 (US$ Million)
Table 13. Global Ureter Cancer Drugs Sales by Manufacturers (2015-2020) (K Pcs)
Table 14. Global Ureter Cancer Drugs Sales Share by Manufacturers (2015-2020)
Table 15. Global Ureter Cancer Drugs Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 16. Global Ureter Cancer Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Ureter Cancer Drugs as of 2019)
Table 17. Ureter Cancer Drugs Revenue by Manufacturers (2015-2020) (US$ Million)
Table 18. Ureter Cancer Drugs Revenue Share by Manufacturers (2015-2020)
Table 19. Key Manufacturers Ureter Cancer Drugs Price (2015-2020) (USD/Pcs)
Table 20. Ureter Cancer Drugs Manufacturers Manufacturing Base Distribution and Headquarters
Table 21. Manufacturers Ureter Cancer Drugs Product Type
Table 22. Date of International Manufacturers Enter into Ureter Cancer Drugs Market
Table 23. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 24. Global Ureter Cancer Drugs Sales by Type (2015-2020) (K Pcs)
Table 25. Global Ureter Cancer Drugs Sales Share by Type (2015-2020)
Table 26. Global Ureter Cancer Drugs Revenue by Type (2015-2020) (US$ Million)
Table 27. Global Ureter Cancer Drugs Revenue Share by Type (2015-2020)
Table 28. Ureter Cancer Drugs Average Selling Price (ASP) by Type 2015-2020 (USD/Pcs)
Table 29. Global Ureter Cancer Drugs Sales by Application (2015-2020) (K Pcs)
Table 30. Global Ureter Cancer Drugs Sales Share by Application (2015-2020)
Table 31. North America Ureter Cancer Drugs Sales by Country (2015-2020) (K Pcs)
Table 32. North America Ureter Cancer Drugs Sales Market Share by Country (2015-2020)
Table 33. North America Ureter Cancer Drugs Revenue by Country (2015-2020) (US$ Million)
Table 34. North America Ureter Cancer Drugs Revenue Market Share by Country (2015-2020)
Table 35. North America Ureter Cancer Drugs Sales by Type (2015-2020) (K Pcs)
Table 36. North America Ureter Cancer Drugs Sales Market Share by Type (2015-2020)
Table 37. North America Ureter Cancer Drugs Sales by Application (2015-2020) (K Pcs)
Table 38. North America Ureter Cancer Drugs Sales Market Share by Application (2015-2020)
Table 39. Europe Ureter Cancer Drugs Sales by Country (2015-2020) (K Pcs)
Table 40. Europe Ureter Cancer Drugs Sales Market Share by Country (2015-2020)
Table 41. Europe Ureter Cancer Drugs Revenue by Country (2015-2020) (US$ Million)
Table 42. Europe Ureter Cancer Drugs Revenue Market Share by Country (2015-2020)
Table 43. Europe Ureter Cancer Drugs Sales by Type (2015-2020) (K Pcs)
Table 44. Europe Ureter Cancer Drugs Sales Market Share by Type (2015-2020)
Table 45. Europe Ureter Cancer Drugs Sales by Application (2015-2020) (K Pcs)
Table 46. Europe Ureter Cancer Drugs Sales Market Share by Application (2015-2020)
Table 47. Asia Pacific Ureter Cancer Drugs Sales by Region (2015-2020) (K Pcs)
Table 48. Asia Pacific Ureter Cancer Drugs Sales Market Share by Region (2015-2020)
Table 49. Asia Pacific Ureter Cancer Drugs Revenue by Region (2015-2020) (US$ Million)
Table 50. Asia Pacific Ureter Cancer Drugs Revenue Market Share by Region (2015-2020)
Table 51. Asia Pacific Ureter Cancer Drugs Sales by Type (2015-2020) (K Pcs)
Table 52. Asia Pacific Ureter Cancer Drugs Sales Market Share by Type (2015-2020)
Table 53. Asia Pacific Ureter Cancer Drugs Sales by Application (2015-2020) (K Pcs)
Table 54. Asia Pacific Ureter Cancer Drugs Sales Market Share by Application (2015-2020)
Table 55. Latin America Ureter Cancer Drugs Sales by Country (2015-2020) (K Pcs)
Table 56. Latin America Ureter Cancer Drugs Sales Market Share by Country (2015-2020)
Table 57. Latin Americaa Ureter Cancer Drugs Revenue by Country (2015-2020) (US$ Million)
Table 58. Latin America Ureter Cancer Drugs Revenue Market Share by Country (2015-2020)
Table 59. Latin America Ureter Cancer Drugs Sales by Type (2015-2020) (K Pcs)
Table 60. Latin America Ureter Cancer Drugs Sales Market Share by Type (2015-2020)
Table 61. Latin America Ureter Cancer Drugs Sales by Application (2015-2020) (K Pcs)
Table 62. Latin America Ureter Cancer Drugs Sales Market Share by Application (2015-2020)
Table 63. Middle East and Africa Ureter Cancer Drugs Sales by Country (2015-2020) (K Pcs)
Table 64. Middle East and Africa Ureter Cancer Drugs Sales Market Share by Country (2015-2020)
Table 65. Middle East and Africa Ureter Cancer Drugs Revenue by Country (2015-2020) (US$ Million)
Table 66. Middle East and Africa Ureter Cancer Drugs Revenue Market Share by Country (2015-2020)
Table 67. Middle East and Africa Ureter Cancer Drugs Sales by Type (2015-2020) (K Pcs)
Table 68. Middle East and Africa Ureter Cancer Drugs Sales Market Share by Type (2015-2020)
Table 69. Middle East and Africa Ureter Cancer Drugs Sales by Application (2015-2020) (K Pcs)
Table 70. Middle East and Africa Ureter Cancer Drugs Sales Market Share by Application (2015-2020)
Table 71. Altor BioScience Corp Corporation Information
Table 72. Altor BioScience Corp Description and Major Businesses
Table 73. Altor BioScience Corp Ureter Cancer Drugs Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 74. Altor BioScience Corp Product
Table 75. Altor BioScience Corp Recent Development
Table 76. Eisai Co Ltd Corporation Information
Table 77. Eisai Co Ltd Description and Major Businesses
Table 78. Eisai Co Ltd Ureter Cancer Drugs Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 79. Eisai Co Ltd Product
Table 80. Eisai Co Ltd Recent Development
Table 81. Exelixis Inc Corporation Information
Table 82. Exelixis Inc Description and Major Businesses
Table 83. Exelixis Inc Ureter Cancer Drugs Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 84. Exelixis Inc Product
Table 85. Exelixis Inc Recent Development
Table 86. GlaxoSmithKline Plc Corporation Information
Table 87. GlaxoSmithKline Plc Description and Major Businesses
Table 88. GlaxoSmithKline Plc Ureter Cancer Drugs Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 89. GlaxoSmithKline Plc Product
Table 90. GlaxoSmithKline Plc Recent Development
Table 91. MedImmune LLC Corporation Information
Table 92. MedImmune LLC Description and Major Businesses
Table 93. MedImmune LLC Ureter Cancer Drugs Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 94. MedImmune LLC Product
Table 95. MedImmune LLC Recent Development
Table 96. Merck & Co Inc Corporation Information
Table 97. Merck & Co Inc Description and Major Businesses
Table 98. Merck & Co Inc Ureter Cancer Drugs Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 99. Merck & Co Inc Product
Table 100. Merck & Co Inc Recent Development
Table 101. Global Ureter Cancer Drugs Sales Forecast by Regions (2021-2026) (K Pcs)
Table 102. Global Ureter Cancer Drugs Sales Market Share Forecast by Regions (2021-2026)
Table 103. Global Ureter Cancer Drugs Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 104. Global Ureter Cancer Drugs Revenue Market Share Forecast by Regions (2021-2026)
Table 105. North America: Ureter Cancer Drugs Sales Forecast by Country (2021-2026) (K Pcs)
Table 106. North America: Ureter Cancer Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 107. Europe: Ureter Cancer Drugs Sales Forecast by Country (2021-2026) (K Pcs)
Table 108. Europe: Ureter Cancer Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 109. Asia Pacific: Ureter Cancer Drugs Sales Forecast by Region (2021-2026) (K Pcs)
Table 110. Asia Pacific: Ureter Cancer Drugs Revenue Forecast by Region (2021-2026) (US$ Million)
Table 111. Latin America: Ureter Cancer Drugs Sales Forecast by Country (2021-2026) (K Pcs)
Table 112. Latin America: Ureter Cancer Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 113. Middle East and Africa: Ureter Cancer Drugs Sales Forecast by Country (2021-2026) (K Pcs)
Table 114. Middle East and Africa: Ureter Cancer Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 115. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 116. Key Challenges
Table 117. Market Risks
Table 118. Main Points Interviewed from Key Ureter Cancer Drugs Players
Table 119. Ureter Cancer Drugs Customers List
Table 120. Ureter Cancer Drugs Distributors List
Table 121. Research Programs/Design for This Report
Table 122. Key Data Information from Secondary Sources
Table 123. Key Data Information from Primary Sources
List of Figures
Figure 1. Ureter Cancer Drugs Product Picture
Figure 2. Global Ureter Cancer Drugs Sales Market Share by Type in 2020 & 2026
Figure 3. Durvalumab Product Picture
Figure 4. Eribulin Mesylate Product Picture
Figure 5. Pembrolizumab Product Picture
Figure 6. Others Product Picture
Figure 7. Global Ureter Cancer Drugs Sales Market Share by Application in 2020 & 2026
Figure 8. In-Patient
Figure 9. Out-Patient
Figure 10. Ureter Cancer Drugs Report Years Considered
Figure 11. Global Ureter Cancer Drugs Market Size 2015-2026 (US$ Million)
Figure 12. Global Ureter Cancer Drugs Sales 2015-2026 (K Pcs)
Figure 13. Global Ureter Cancer Drugs Market Size Market Share by Region: 2020 Versus 2026
Figure 14. Global Ureter Cancer Drugs Sales Market Share by Region (2015-2020)
Figure 15. Global Ureter Cancer Drugs Sales Market Share by Region in 2019
Figure 16. Global Ureter Cancer Drugs Revenue Market Share by Region (2015-2020)
Figure 17. Global Ureter Cancer Drugs Revenue Market Share by Region in 2019
Figure 18. Global Ureter Cancer Drugs Sales Share by Manufacturer in 2019
Figure 19. The Top 10 and 5 Players Market Share by Ureter Cancer Drugs Revenue in 2019
Figure 20. Ureter Cancer Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 21. Global Ureter Cancer Drugs Sales Market Share by Type (2015-2020)
Figure 22. Global Ureter Cancer Drugs Sales Market Share by Type in 2019
Figure 23. Global Ureter Cancer Drugs Revenue Market Share by Type (2015-2020)
Figure 24. Global Ureter Cancer Drugs Revenue Market Share by Type in 2019
Figure 25. Global Ureter Cancer Drugs Market Share by Price Range (2015-2020)
Figure 26. Global Ureter Cancer Drugs Sales Market Share by Application (2015-2020)
Figure 27. Global Ureter Cancer Drugs Sales Market Share by Application in 2019
Figure 28. Global Ureter Cancer Drugs Revenue Market Share by Application (2015-2020)
Figure 29. Global Ureter Cancer Drugs Revenue Market Share by Application in 2019
Figure 30. North America Ureter Cancer Drugs Sales Growth Rate 2015-2020 (K Pcs)
Figure 31. North America Ureter Cancer Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 32. North America Ureter Cancer Drugs Sales Market Share by Country in 2019
Figure 33. North America Ureter Cancer Drugs Revenue Market Share by Country in 2019
Figure 34. U.S. Ureter Cancer Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 35. U.S. Ureter Cancer Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 36. Canada Ureter Cancer Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 37. Canada Ureter Cancer Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 38. North America Ureter Cancer Drugs Market Share by Type in 2019
Figure 39. North America Ureter Cancer Drugs Market Share by Application in 2019
Figure 40. Europe Ureter Cancer Drugs Sales Growth Rate 2015-2020 (K Pcs)
Figure 41. Europe Ureter Cancer Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 42. Europe Ureter Cancer Drugs Sales Market Share by Country in 2019
Figure 43. Europe Ureter Cancer Drugs Revenue Market Share by Country in 2019
Figure 44. Germany Ureter Cancer Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 45. Germany Ureter Cancer Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 46. France Ureter Cancer Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 47. France Ureter Cancer Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 48. U.K. Ureter Cancer Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 49. U.K. Ureter Cancer Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 50. Italy Ureter Cancer Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 51. Italy Ureter Cancer Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 52. Russia Ureter Cancer Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 53. Russia Ureter Cancer Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 54. Europe Ureter Cancer Drugs Market Share by Type in 2019
Figure 55. Europe Ureter Cancer Drugs Market Share by Application in 2019
Figure 56. Asia Pacific Ureter Cancer Drugs Sales Growth Rate 2015-2020 (K Pcs)
Figure 57. Asia Pacific Ureter Cancer Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 58. Asia Pacific Ureter Cancer Drugs Sales Market Share by Region in 2019
Figure 59. Asia Pacific Ureter Cancer Drugs Revenue Market Share by Region in 2019
Figure 60. China Ureter Cancer Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 61. China Ureter Cancer Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 62. Japan Ureter Cancer Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 63. Japan Ureter Cancer Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 64. South Korea Ureter Cancer Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 65. South Korea Ureter Cancer Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 66. India Ureter Cancer Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 67. India Ureter Cancer Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 68. Australia Ureter Cancer Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 69. Australia Ureter Cancer Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 70. Taiwan Ureter Cancer Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 71. Taiwan Ureter Cancer Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 72. Indonesia Ureter Cancer Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 73. Indonesia Ureter Cancer Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 74. Thailand Ureter Cancer Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 75. Thailand Ureter Cancer Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 76. Malaysia Ureter Cancer Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 77. Malaysia Ureter Cancer Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 78. Philippines Ureter Cancer Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 79. Philippines Ureter Cancer Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 80. Vietnam Ureter Cancer Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 81. Vietnam Ureter Cancer Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 82. Asia Pacific Ureter Cancer Drugs Market Share by Type in 2019
Figure 83. Asia Pacific Ureter Cancer Drugs Market Share by Application in 2019
Figure 84. Latin America Ureter Cancer Drugs Sales Growth Rate 2015-2020 (K Pcs)
Figure 85. Latin America Ureter Cancer Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 86. Latin America Ureter Cancer Drugs Sales Market Share by Country in 2019
Figure 87. Latin America Ureter Cancer Drugs Revenue Market Share by Country in 2019
Figure 88. Mexico Ureter Cancer Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 89. Mexico Ureter Cancer Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 90. Brazil Ureter Cancer Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 91. Brazil Ureter Cancer Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 92. Argentina Ureter Cancer Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 93. Argentina Ureter Cancer Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 94. Latin America Ureter Cancer Drugs Market Share by Type in 2019
Figure 95. Latin America Ureter Cancer Drugs Market Share by Application in 2019
Figure 96. Middle East and Africa Ureter Cancer Drugs Sales Growth Rate 2015-2020 (K Pcs)
Figure 97. Middle East and Africa Ureter Cancer Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 98. Middle East and Africa Ureter Cancer Drugs Sales Market Share by Country in 2019
Figure 99. Middle East and Africa Ureter Cancer Drugs Revenue Market Share by Country in 2019
Figure 100. Turkey Ureter Cancer Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 101. Turkey Ureter Cancer Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 102. Saudi Arabia Ureter Cancer Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 103. Saudi Arabia Ureter Cancer Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 104. U.A.E Ureter Cancer Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 105. U.A.E Ureter Cancer Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 106. Middle East and Africa Ureter Cancer Drugs Market Share by Type in 2019
Figure 107. Middle East and Africa Ureter Cancer Drugs Market Share by Application in 2019
Figure 108. North America Ureter Cancer Drugs Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 109. North America Ureter Cancer Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 110. Europe Ureter Cancer Drugs Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 111. Europe Ureter Cancer Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 112. Asia Pacific Ureter Cancer Drugs Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 113. Asia Pacific Ureter Cancer Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 114. Latin America Ureter Cancer Drugs Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 115. Latin America Ureter Cancer Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 116. Middle East and Africa Ureter Cancer Drugs Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 117. Middle East and Africa Ureter Cancer Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 118. Porter's Five Forces Analysis
Figure 119. Channels of Distribution
Figure 120. Distributors Profiles
Figure 121. Bottom-up and Top-down Approaches for This Report
Figure 122. Data Triangulation
Figure 123. Key Executives Interviewed
頭頸部がん治療薬/治療の世界市場（～2026年） Head and neck cancer is a group of cancers that starts in the mouth, nose, throat, larynx, sinuses, or salivary glands. Current trends indicate that rising geriatric population worldwide, growing cases of target diseases, and availability of improved healthcare services due to government and private…- 腎臓/腎がん治療薬の世界市場（～2026年） Kidney/Renal Cancer Drugs are used to cure kidney cancers. The market is primarily driven by lifestyle affecting factors such as reduced physical activity, excessive smoking and drinking. Rising aging population and the mounting prevalence of kidney cancer cases are some of the additional factors bo…
- 腫瘍学/がん治療薬の世界市場（～2026年） Cancer Treatment Drugs are used to treat malignancies, or cancerous growths. Depending on the technology it cans classification into Chemotherapy, Targeted Therapy, Immunotherapy (Biologic Therapy), Hormonal Therapy and Others. Oncology Drugs is widely used For Blood Cancer, Breast Cancer, Gastroint…
- 精巣腫瘍治療薬の世界市場（～2026年） Market Analysis and Insights: Global Testicular Cancer Drugs Market The global Testicular Cancer Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Testicular Cancer Drugs Scope and Market Size Testicular Cancer Dru…
- 胃がん治療薬の世界市場（～2026年） Gastric cancer drugs are used to treat malignancies, or cancerous growths. The APAC region to account for the highest market share during the forecast period. Much of this region’s growth can be attributed to the increasing demand for better healthcare infrastructure, which results in its massive ma…